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Abstract
Background: Signal Transducer and Activator of Transcription 5 (STAT5) plays critical roles in normal and leukemic
hematopoiesis. However, the manner in which STAT5 responds to early-acting and lineage-restricted cytokines, particularly
in leukemic stem/progenitor cells, is largely unknown.
Methodology/Principal Findings: We optimized a multiparametric flow cytometry protocol to analyze STAT5
phosphorylation upon cytokine stimulation in stem and progenitor cell compartments at a single-cell level. In normal
cord blood (CB) cells, STAT5 phosphorylation was efficiently induced by TPO, IL-3 and GM-CSF within CD34
+CD38
2
hematopoietic stem cells (HSCs). EPO- and SCF-induced STAT5 phosphorylation was largely restricted to the
megakaryocyte-erythroid progenitor (MEP) compartment, while G-CSF as well IL-3 and GM-CSF were most efficient in
inducing STAT5 phosphorylation in the myeloid progenitor compartments. Strikingly, mobilized adult peripheral blood (PB)
CD34
+ cells responded much less efficiently to cytokine-induced STAT5 activation, with the exception of TPO. In leukemic
stem and progenitor cells, highly distinct cytokine responses were observed, differing significantly from their normal
counterparts. These responses could not be predicted by the expression level of cytokine receptors. Also, heterogeneity
existed in cytokine requirements for long-term expansion of AML CD34
+ cells on stroma.
Conclusions/Significance: In conclusion, our optimized multiparametric flow cytometry protocols allow the analysis of
signal transduction at the single cell level in normal and leukemic stem and progenitor cells. Our study demonstrates highly
distinctive cytokine responses in STAT5 phosphorylation in both normal and leukemic stem/progenitor cells.
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Introduction
Hematopoiesis is largely regulated by signaling cascades that are
activated by a wide variety of cytokines [1]. The signals that
emanate from cytokine receptors are translated into specific
cellular responses via activation of transcription factors that induce
expression of unique sets of target genes. One family of such
transcription factors is the Signal Transducer and Activator of
Transcription (STAT) family, which consists of 7 members,
STAT1-6 whereby STAT5A and STAT5B are encoded by two
separate genes. STAT5 is widely expressed throughout the
hematopoietic system, targeting genes that have been associated
with proliferation, anti-apoptosis or differentiation [2–4]. Loss-of-
function studies demonstrated that long-term repopulating activity
of hematopoietic stem cells (HSC) was impaired in STAT5A-
deficient HSCs [5–7]. During steady-state hematopoiesis, condi-
tional deletion of STAT5 in nonablated adult mouse gradually
reduced the HSC pool size and caused loss of HSC quiescence [8].
Our previous studies on STAT5 downregulation also showed
impaired maintenance and expansion of primitive human
hematopoietic stem and progenitor cells [9,10]. Stress-induced
erythropoiesis was severely impaired in STAT5
2/2 mice [11], and
appropriated STAT5 signaling was also required for maintaining a
normal lymphoid-myeloid balance [12]. Conversely, in gain-of-
function studies overexpression of activated STAT5A in CB
CD34
+ cells resulted in enhanced stem cell self-renewal and
erythroid commitment, at the expense of normal myelopoiesis and
megakaryocyte development [13–15]. Introduction of a persis-
tently activated STAT5A mutant (S711F) enabled erythropoiesis
in an EPO-independent manner [16]. Together these studies
demonstrated critical roles for STAT5 in various hematopoietic
compartments.
Constitutive STAT5 signaling has been identified in the
pathogenesis of various hematological malignancies, including
BCR-ABL-induced chronic myeloid leukemia (CML), acute
myeloid leukemia (AML), acute lymphoid leukemia (ALL) and
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cytic leukemia (CMML) and polycythemia vera (PV) [4]. In AML,
constitutive STAT5 signaling is observed in the majority of cases,
resulting from either mutations in upstream receptor tyrosine
kinases such as FLT3 and c-KIT, or autocrine growth factor
production [17–20]. In primary human AML CD34
+ cells,
lentiviral downregulation of STAT5 resulted in impaired long-
term expansion and self-renewal on stroma [9].
Despite increasing evidence indicating a critical role for STAT5
in normal and leukemic hematopoiesis, little is known about how
STAT5 responds to different early-acting and lineage-restricted
cytokines. Since a lot of studies investigated STAT5 activity in bulk
populations, it has been particularly unclear whether and when
STAT5 is activated upon cytokine stimulation within individual
cells in stem cell and progenitor compartments. Also, it has been
unclear whether constitutive STAT5 activity is specifically present
in leukemic stem cell-enriched populations, or predominantly
within the non-self-renewing leukemic progeny. In the current
study, we have optimized multiparametric FACS protocols in order
to evaluate activation of the STAT5 signal transduction pathway in
specific hematopoietic stem cell and progenitor subpopulations,
both in normal human cord blood (CB) and peripheral blood (PB),
as well as in primary AML patient samples. Our current study
reveals highly distinct cytokine responses in normal and leukemic
stem and progenitor subpopulations.
Results
Cytokine-Induced STAT5 Phosphorylation in Normal
Stem/Progenitor Cells Derived from CB and PB Cells
To test the affinity and specificity of phospho-STAT5 (pSTAT5)
antibodies for FACS procedures, the cytokine-dependent UT-7 cell
line and BCR-ABL posititive K562 cell line were used. UT-7 cells
were cytokine-depleted overnight followed by EPO stimulation over
several time points. The kinetics of pSTAT5 observed by Western
blotting (Fig. S1A) fitted well with that observed in FACS analysis
(Fig. S1B and S1C). Constitutively activated STAT5 could be
observed in the BCR-ABL-positive K562 cell line, whereby
downregulation of pSTAT5 upon treatment with imatinib was
observed in both Western blotting and FACS experiments (Fig.
S1D-F). Furthermore, we wished to compare the staining properties
of membrane markers necessary for discriminating stem cell and
progenitor compartments in paraformaldehyde and methanol
(F/M)-treated conditions versus non-fixed conditions. Antibodies
against CD34, CD38, CD123, CD45RA and CD110 were titrated
in CB CD34
+ cells in both non-fixed and F/M-treated conditions to
obtain optimal separation (all titration results are shown in Fig. S2).
As previously described, these antibodies have previously been
shown to discriminate between BFU-Us, CFU-GM and CFU-
GEMM progenitor cells [21–23]. Various tested antibodies were
insufficient in separating HSC, common myeloid progenitors
(CMP), granulocyte-macrophage progenitors (GMP) and megakar-
yocyte-erythroid progenitors (MEP) under F/M-treated conditions,
but ultimately we were able to identify a set of antibodies with
which the various compartments could be visualized by FACS
under F/M-treated conditions (Fig. S3).
Our FACS protocol was first tested in CB CD34
+ cells
stimulated with FL, SCF, TPO, IL-3, GM-CSF, G-CSF and
EPO for 15 minutes at different concentrations. As displayed in
Figure 1A, EPO induced a strong STAT5 phosphorylation within
the MEP compartment, while no STAT5 phosphorylation was
observed within the GMP compartment. Conversely, G-CSF-
induced STAT5 phosphorylation was easily detected within CMP
and GMP compartments, but not within the MEP compartment.
We quantified the STAT5 responses by multiplying the percent-
age of positive cells with the mean fluorescence intensity (% x MFI,
displayed in Fig. 1B) whereby isotype controls were used to set the
gates for negative populations. Thus, these data provide further
validation for the gate definitions of the progenitor subpopulations
in our FACS protocols. Furthermore, variable cytokine-induced
STAT5 responses were observed within the different compart-
ments. FL was not sufficient in activating STAT5 in either stem or
progenitor cells, in line with previous observations [24]. SCF
induced a strong activation of STAT5 in the MEP, but not in the
HSC. Within the HSC compartments, STAT5 could only be
efficiently activated by TPO and high concentrations of IL-3 and
GM-CSF. IL-3 and GM-CSF also activated STAT5 in the CMP
and GMP compartments, but much less efficiently in the MEP.
TPO could activate STAT5 in the HSC, CMP and MEP, and to a
lesser extent in the GMP (Fig. 1A and 1B).
To be able to compare cytokine responses in fetal versus adult
stem/progenitor cells, we also studied STAT5 activation in G-
CSF-mobilized PB CD34
+ cells (Fig. 1C). Strikingly, PB CD34
+
cells responded strongly to TPO stimulation in all cell compart-
ments, comparable to CB, but none of the other cytokines was able
to efficiently induce STAT5 phosphorylation at the tested
concentrations in PB. The absence of STAT5 phosphorylation
was also confirmed by Western blotting of the bulk CD34
+ PB
population (Fig. 1D). While TPO also induced strong phosphor-
ylation of ERK1/2 and STAT3 in PB CD34
+ cells, none of these
pathways was activated by any of the other tested cytokines.
Heterogeneity in Cytokine-Induced STAT5
Phosphorylation in AML Stem/Progenitor Cells
Next, we studied cytokine-induced STAT5 activation in
primary AML samples (n=10, Table 1). We followed the same
definitions for HSC, CMP, GMP and MEP as in healthy CB and
PB using CD34, CD38, CD123 and CD45RA as antigens,
although it needs to be pointed out that these definitions of stem
and progenitor compartments might not be valid in AML due to
alterations in antigen expression. Nevertheless, for the sake of
clarity we shall maintain this nomenclature throughout the
manuscript. The CD34
2 population within the mononuclear
leukemic blast fraction was also included in our analyses, and the
same cytokines were used to stimulate the AML PB cells as
previously in healthy CB and PB. The results are shown in
Figure 2A, and the raw FACS data were included as
supplemental Figure S4A-J. In general, we observed that
cytokine-induced STAT5 activation was highly variable through-
out AML samples. When the complete CD34
+ compartment was
taken into account, 6 out of 10 AMLs responded to TPO, 6 out
of 10 to G-CSF, 8 out of 10 to IL-3 and 4 out of 6 to GM-CSF
(Table 1, Fig. 2A and Fig. S4A-J). No STAT5 phosphorylation
was observed in response to SCF, FL or EPO in any of the
investigated AML samples. When analyzing the HSC and MPP
(CD34
+CD38
+) compartments, in many cases (6 out of 10) a
strong shift from the MEP/CMP compartments towards the
GMP was observed, possibly highlighting the myeloid character
of the leukemias that were studied. Also since no EPO-induced
STAT5 activation was observed in any of the investigated cases,
the MEP fraction as defined by CD34
+/CD38
+/CD45RA
2/
CD123
2 might not be a true representation of the erythroid
progenitor compartment in AML. No explicit differences in
cytokine-induced STAT5 responses were observed between the
different HSC and MPP compartments, indicating that in case an
AML responded to TPO, this was observed in both leukemic
stem cells as well as in leukemic progenitors. Interestingly, in 3
out of 10 cases the most dominant cytokine-induced STAT5
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2 fraction, particu-
larly in response to IL-3 or GM-CSF (Table 1, Fig. 2A and Fig.
S4A–J). Together, these data indicate that cytokine-induced
STAT5 phosphorylation is distinct in AML cases, and differs
compared to normal hematopoietic cells.
The Basal Cytokine-Induced STAT5 Phosphorylation in
AMLs with FLT3 Wild Type Versus FLT3-ITD
Constitutive STAT5 phosphorylation was observed in 5 AML
cases (Fig. 2B, Table 1). Three of these AMLs contained FLT3
internal tandem duplication (FLT3-ITD) mutations while 2 had
Figure 1. STAT5 phosphorylation in defined stem and progenitor cell populations in normal hematopoietic cells. (A) Normal CD34
+
cells isolated from cord blood (CB) were expanded in HPGM supplemented with 100 ng/ml SCF, FL and TPO for 3 days. Cells were washed and
cytokine-depleted in HPGM overnight and then stimulated with indicated cytokines for 15 minutes, followed by intracellular FACS. The scatter
properties and gating schemes are shown. The red dots represent the cells with activated STAT5 upon stimulation. (B) Overview of cytokine
responses in STAT5 activation in CB CD34
+ cells quantified as the percentage of positive cells multiplied with the mean fluorescence intensity (MFI).
(C) Normal CD34
+ cells derived from mobilized peripheral blood (PB) were suspended in HPGM for 2 hours, followed by cytokine stimulation and
intracellular FACS. (D) 1610
6/ml PB CD34
+ cells were isolated and suspended in HPGM for 2 hours. Cells were stimulated with 1.0 ng/ml IL-3 (I),
100 ng/ml G-CSF (G) or 100 ng/ml TPO (T) for 15 minutes or left unstimulated (indicated as U), after which cell lysates were prepared and subjected
to Western blotting using antibodies as indicated.
doi:10.1371/journal.pone.0007989.g001
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we could not observe constitutive activation of STAT5. In the
FLT3-ITD AMLs, AML 2003-114 and 2004-168 showed
constitutive STAT5 activity, which was observed in HSC and
MPPs, as well as within the CD34
2 fraction. In AML 2003-119
constitutive STAT5 activity was detected in the CMP/GMP, but
not HSC compartment. In the FLT3-wt AMLs, the constitutive
STAT5 activation varied between HSC and MPP fractions,
whereby AML 2007-272 contained high constitutive STAT5
activation within the HSCs, while the STAT5 activation in AML
2005-016 was more pronounced within the CMP/GMP fractions.
Remarkably, in all AMLs characterized by constitutive STAT5
activation, a strongly reduced cytokine response was observed
(Fig. 2A and Fig. S4A-J), possibly suggesting the constitutive
STAT5 signaling resulted in activation of negative feedback loops
which render cells relatively insensitive to additional cytokine
input. Indeed, in gene expression studies we observed that the
negative feedback gene SOCS2 was specifically upregulated in
these AMLs with constitutive STAT5 activity (data not shown).
Cytokine Receptor Expression Does Not Predict
Downstream Signaling in AML Stem/Progenitor Cells
To investigate whether the differences in cytokine responses
resulted from differences in expression levels of cytokine and
growth factor receptors, we analyzed the surface marker
expression by FACS (Fig. 3A). In normal cells, the TPOR
(CD110) was mainly expressed in MEPs in both CB and PB
CD34
+ fraction, with some expression in HSCs, CMPs and GMPs
as well. The TPO response was higher in MEP fraction and almost
equal in HSCs, CMPs and GMPs in both PB and CB cells
(Fig. 1A–1C). In CB CD34
+ cells, the G-CSFR (CD114) was
expressed in 73% of GMPs, 29% of HSC and 21% of CMPs, but
not within MEPs. Similarly, the GM-CSFRa (CD116) was also
predominantly expressed within the GMP compartment in CB
CD34
+ cells. The expression levels of G-CSFR and GM-CSFRa
were much lower in PB CD34
+ cells, which may explain the poor
induction of STAT5 phosphorylation by these two cytokines in PB
CD34
+ cells (Fig. 3A, Fig. 1A–1C). IL-3Ra (CD123) was analyzed
in HSC and MPPs (CD34
+CD38
+) because it was used to define
CMPs/GMPs (as CD123
+) and MEPs (as CD123
2). In CB cells,
CD123 was expressed in both HSCs and MPPs (42% and 54%
respectively), which was in line with our observations regarding the
IL-3-inducibility of STAT5 in these compartments (Fig. 1A). In PB
Figure 2. STAT5 phosphorylation in defined stem and progen-
itor cell populations in AML cases. AML PB mononuclear cells
(MNCs) were thawed and suspended at 1.5610
6/ml in HPGM for 2 hours
at 37uC. Cells were stimulated with cytokines for 15 minutes, followed
by intracellular FACS. Panel (A) displays STAT5 phosphorylation in 6
AMLs with or without indicated cytokine stimulations. Panel (B) displays
the basal levels of STAT5 phosphorylation (in unstimulated condition)
of AML samples with FLT3-ITD versus FLT3-wild type. Data are
presented as the multiplied value of the percentage of positive cells
with the mean fluorescence intensity (MFI).
doi:10.1371/journal.pone.0007989.g002
Table 1. Summary of clinical parameters of AML patients
used in this study.
Patient
ID FAB
%
CD34 Karyotype FLT3-ITD
Responses to
cytokines
2003-119 M0 80 N + c.a. TPO, IL-3, GM-CSF
2005-258 M0 73 -5q; +6 ND G-CSF, IL-3
2006-014 M1 19 N + TPO, IL-3 GM-CSF
2005-016 M1 65 N 2 c.a., G-CSF
2004-168 M2 21 del (9) (q12;q22) + c.a., TPO, IL-3
2007-046 M2 20 N + TPO, G-CSF, IL-3
2003-152 M4 72 Inv (16) 2 TPO, G-CSF, IL-3
2005-289 M5 95 N 2 IL-3, GM-CSF, G-CSF
2003-114 M5 27 t(11;20) + c.a., G-CSF, GM-CSF
2007-272 M7 36 Complex 2 c.a. TPO, IL-3
AML cells derived from peripheral blood (PB); Percentage of CD34
+ (% CD34) in
the total AML mononuclear cell fraction; FAB, French-American-British
classifications; FLT3-ITD (internal tandem duplication) was present (+) or absent
(2) in the AML cells; ND, not determined; N, normal; c.a. constitutive activation
of STAT5.
doi:10.1371/journal.pone.0007989.t001
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+ cells, CD123 was expressed at much lower levels (18% of
MPPs). These results are consistent with a previous study, in which
CD123 was identified as a marker for long-term repopulating cells
in CD34
+CD38
2 fraction from bone marrow, cord blood and
AMLs [25]. However, in other studies it was suggested that the
CD34
+/CD38
2 HSC does not express CD123 [26]. We have
observed that upon isolation, about 40% of CB CD34
+/CD38
2
cells express CD123 with low MFI, which was up by 3-fold upon
culturing in HPGM supplemented with SCF, FL and TPO for 3–5
days (data not shown). To study the cytokine responses within the
HSC compartment in more detail, we gated the CD34
+/CD38
2
cells into CD123
+ and CD123
2 compartments and analyzed
cytokine-induced STAT5 phosphorylation. As shown in Supple-
mental Figure S5, the CD34
+/CD38
2/CD123
2 compartment
was unresponsive to IL-3, GM-CSF or G-CSF, while STAT5 was
readily activated by these cytokines within the CD34
+/CD38
2/
CD123
+ compartment. Only TPO and EPO were able to activate
STAT5 within CD34
+/CD38
2/CD123
2 cells.
We also tested cytokine receptor expression in 6 AML samples.
In general, the receptor expression level did not predict the level of
cytokine-induced STAT5 activation (Fig. 3A, cytokine responses
are indicated below the graphs). For example, AML 2003-119 was
highly responsive to TPO stimulation, but expressed only
relatively low levels of the TPOR. AML 2005-016 was highly
G-CSF-responsive, but its G-CSFR expression was similar or even
lower compared to e.g. AML 2003-119 and AML 2007-272,
Figure 3. Cytokine and growth factor receptor expression in normal and leukemic cells. The expression of receptors for TPO (CD110), GM-
CSF (CD116), IL-3 (CD123) and G-CSF (CD114) was analyzed by FACS. (A) MNCs from AML samples and CD34
+ cells CB and PB were stained with
antibodies against receptors, together with CD34, CD38, CD45RA and CD123 for 30 minutes. CD123 expression was analyzed in HSCs, MPPs
(CD34
+CD38
+) and CD34
2 populations. For CB cells, no CD34
2 fraction was available. The cytokine responses for STAT5 activation in CD34
+ versus
CD34
2 populations are also indicated (‘‘+’’ indicates that STAT5 was activated by the respective cytokine; ‘‘2’’ indicates that STAT5 was not activated).
(B) 1610
6/ml CD34
+ cells were sorted by MoFlo from AML MNCs and suspended in HPGM for 2 hours. Cells were harvested after stimulation with
1.0 ng/ml IL-3 (I), 100 ng/ml G-CSF (G) or 100 ng/ml TPO (T) for 15 minutes or left unstimulated (indicated as U) for Western bloting. ND, not
determined.
doi:10.1371/journal.pone.0007989.g003
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CSFRa expression was observed in CD34
2 cells in the majority of
AML cases, which did correlate with a strong GM-CSF-induced
STAT5 phosphorylation within those cells (Fig. 2A and 3A). Since
some cytokines were unable to induce STAT5 phosphorylation in
some cases, we tested whether additional pathways could be
activated in those AMLs in order to verify whether the receptors
would be functional. Activation of the RAS/MEK/ERK,
mTOR//4E-BP1/p70S6k and STAT3 signal transduction path-
ways were analyzed by Western blotting in the bulk CD34
+
compartment given their importance in AML cell survival [27,28].
We observed that all cytokine-induced STAT5 phosphorylation
patterns that we observed by intracellular FACS were recapitu-
lated in our Western blot analyses (Fig. 3B). While the constitutve
STAT5 phosphorylation in AML 2007-272 was readily detected
by Western blotting, the basal levels of pSTAT5 of AML 2003-
119, 2003-114 and 2005-016 were not detected although
constitutive levels were found in FACS analysis, reflecting a
higher sensitivity of FACS compared Western blotting. Further-
more, we observed that in cases where e.g. G-CSF was unable to
activate STAT5, STAT3 or ERK phosphorylation was readily
induced (AML 2005-289 and AML 2003-119), indicating that in
those cases the receptor complexes were clearly able to induce
downstream signal transduction.
Differential Cytokine Requirements for Long-Term In
Vitro Expansion of AML CD34
+ Cells on Bone Marrow
Stroma
Previously, we observed that STAT5 knockdown impaired long-
term growth of leukemic CD34
+ cells, indicating that STAT5
signaling was required for AML growth [9]. We now wondered
whether AMLs would depend on specific cytokines for long-term
proliferation on MS5 stromal cells, since heterogeneity was
observed in AML cases with regard to their responses to
cytokine-induced activation of STAT5. CD34
+ cells were sorted
from 6 AML samples and plated on MS5 stroma with IL-3, G-
CSF, TPO and combinations thereof (Fig. 4). With the exception
of AML 2005-289, long-term expanding cocultures could be
established reaching 4- to 25-fold expansion, after 4 weeks of
culture. All AMLs (except one: AML 2003-114) were dependent
on cytokines for growth on stroma. Although AML 2003-119,
AML 2007-272 and AML 2005-016 were characterized by
constitutively activated STAT5, no long-term expansion was
observed without cytokines. AML 2003-114, whereby long-term
cultures could be established in the absence of cytokines, also
contained constitutively activated STAT5. Interestingly, addition
of G-CSF, either alone or in combinations with other cytokines,
impaired long-term growth of this AML. Apparently, G-CSF
activated certain signaling pathways that negatively regulated cell
proliferation or induced differentiation. It is notable that AML
2003-119, in which STAT5 phosphorylation was strongly induced
by TPO, but not G-CSF, no long-term cultures could be
established with TPO alone. In contrast, addition of G-CSF was
sufficient to initiate long-term expansion, although maximal
expansion was reached in cultures where all cytokines were
added. Together, these data indicate that heterogeneity exists in
the cytokine requirement of AML CD34
+ cells for long-term
expansion in our in vitro stromal cocultures, and that in some
cases constitutive STAT5 phosphorylation is not sufficient to
confer cytokine-independent growth.
Figure 4. Variability in cytokine-dependent long-term expansion of AML CD34
+ cells on MS5 stroma. 4610
5 AML CD34
+ cells were
sorted and plated in 12-well plates precoated with MS5 stromal cells. Cells were expanded in LTC medium supplemented with 20 ng/ml IL-3, G-CSF,
TPO, combinations thereof, or without any cytokines. Cultures were demi-depopulated weekly for analysis. Weekly cumulative cell counts
represented cells in suspension. The cytokines above the figures indicate which cytokines were able to induce STAT5 phosphorylation. c.a. indicates
constitutive activation of STAT5.
doi:10.1371/journal.pone.0007989.g004
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STAT5 in Response to Cytokine in Normal HSC Versus
MPPs
The current study demonstrates that intracellular FACS
analysis is a very useful tool to dissect cytokine-induced signal
transduction in single cells within normal and leukemic stem and
progenitor compartments. Although various studies have shown
that STAT5 can be activated by a plethora of cytokines, including
FL, SCF, TPO, IL-3, G-CSF, GM-CSF and EPO, subsequently
affecting the self-renewal and hematopoietic differentiation
program, less has been revealed about how the STAT5 signaling
pathway specifically responds to cytokine stimulation within the
rare stem cells, or hematopoietic progenitor subfractions.
Loss-of-function studies have implicated STAT5 as an important
regulator of HSC function [5–7], although little information has
been available on the growth factors and cytokines that induce
STAT5 within the human hematopoietic stem cell compartment.
Within the human CB CD34
+/CD38
2 HSC compartment,
STAT5 activation could be induced by TPO and high concentra-
tions of IL-3 and GM-CSF. In murine HSCs, TPO-induced
STAT5 signaling has been associated with enhanced self-renewal
and improved competitive repopulation, in particular in Lnk
2/2
HSCs which display hypersensitivity for TPO-induced STAT5
phosphorylation [29]. In human PBSCs, multilineage engraftment
ability in NOD/SCID mice could be maintained by expansion in
serum-free medium containing TPO, SCF and FL [30], and this
cytokine cocktail is used in many studies to expand human CB
CD34
+ stem/progenitor cells e.g. in retroviral gene-targeting
experiments [2,22]. While we did observe that SCF was able to
induce STAT5 activity in the MEP, no STAT5 phosphorylation
was induced within the HSC. FL was unable to induce STAT5
phosphorylation in any of the hematopoietic compartments, in
agreement with previously published observations [24], even
though its receptor FLT3 was highly expressed at the HSC and
CMP/GMP progenitor stages in human CD34
+ cells from both
bone marrow and cord blood [31]. Thus, it appears that in human
stem cell expansion protocols it is particularly TPO that acts on
HSCs, at least in terms of STAT5 signaling. In line with these
observations, previous studies on STAT5-deficient bone marrow
showed overlappingactivities in HSC self-renewal capacity between
STAT5AB
DN/DN and c-MPL
2/
2 mice, although not all the
STAT5
2/2 defects could be accounted for by loss of TPO signaling
[6]. While mostly associated with signaling in myeloid progenitors,
IL-3 and GM-CSF were able to activate STAT5 in HSCs as well.
The role these factors fulfill in human HSCs has not been fully
elucidated yet, but it has been observed that the responsiveness of
STAT5AB
DN/DN HSCs to early-acting cytokines such as IL-3 was
reduced, while the sensitivity to 5-fluorouracil was enhanced [5]. In
agreement with previous published studies [25,32], we find that the
IL-3Ra (CD123) is indeed expressed within a subset of CD34
+/
CD38
2 cells. When cytokine signaling was evaluated within the
CD123
+ and CD123
2 HSC compartments we observed that the
CD34
+/CD38
2/CD123
2 compartment was unresponsive to IL-3,
GM-CSF or G-CSF, while STAT5 was readily activated by these
cytokines within the CD34
+/CD38
2/CD123
+ compartment. Only
TPO and EPO were able to activate STAT5 within CD34
+/
CD38
2/CD123
2 cells. Further studies will be required to
determine whether both of these subpopulations contain in vivo
repopulating activity.
In the erythroid progenitor compartment, STAT5 was activated
by EPO, SCF and TPO. Gene knockout studies have revealed that
STAT5 expression is required to prevent apoptosis during fetal
development [33], surprisingly much more modest effects were
observed on e.g. EPO and TPO signaling during adult steady-state
hematopoiesis [34]. In the MEP, STAT5 fulfils an important anti-
apoptotic role by upregulating Bcl-Xl [11,35,36], although a more
direct role in initiating erythroid commitment might exist as well
[15]. In myeloid progenitor cells, we find that STAT5 is activated
by IL-3, GM-CSF and G-CSF. Since myelopoiesis appeared to be
relatively unaffected in STAT5
2/2 mice [12]. The exact role of
STAT5 in myeloid progenitors remains elusive [12], although it is
well possible that the signals initiated by e.g. IL-3 and GM-CSF
regulate myeloproliferation or anti-apoptosis in these progenitor
subsets as well [37–39].
Fetal stem/progenitor cells CD34
+ cells isolated from cord blood
might differ from adult stem/progenitor cells in various aspects, and
therefore we included mobilized adult PB CD34
+ cells in our
analyses as well. Strikingly, only TPO was able to induce a robust
STAT5 phosphorylation in PB CD34
+ cells, while all other tested
cytokines failed to activate STAT5 at the concentrations used in this
study. Indeed, while the TPO receptor CD110 was expressed at
comparable levels in CB and PB CD34
+ cells, the expression of
CD114,CD116 and CD123was significantlylowerinPB.However,
it cannot be excluded that the in vivo applied G-CSF might have
affected the receptor expression and down-stream signaling of the
collected CD34
+ cells. Exposure to recombinant human G-CSF
causes down-regulation of G-CSF receptor and an increase in serum
levels of growth factors including IL-8, vascular-endothelial growth
factor (VEGF) and transforming growth factor beta (TGF-b), etc,
subsequently modulating the cytokine responses and networks [40].
In MNCs isolated from BM, we did observe that STAT5 could be
activated by G-CSF, TPO and IL-3 (data not shown). Our results are
in line with a previous study in which primary CD34
+CD41
+
megakaryocytic progenitors isolated from mobilized PBSCs, where-
by SCF stimulation alone did not induce detectable STAT5
activation, but prestimulation with SCF enhanced and prolonged
TPO-induced STAT5 phosphorylation [41].
STAT5 Signaling in Leukemic Stem and Progenitor Cells
In the vast majority of cases, leukemic cells remain dependent
on cytokines for growth [42]. In order to establish long-term in
vitro AML cocultures, the addition of exogenous human cytokines
was required [43,44], and also in vivo engraftment of human
primary AML samples in NOD-SCID mice has been shown to be
facilitated by the addition of human cytokines [45,46]. Yet, the
specific cytokine-dependency of individual subtypes of AML has
not been studied in detail, and cytokine-induced signal transduc-
tion in leukemic stem cell-enriched populations versus more
committed leukemic progeny is only beginning to be examined.
We observed that cytokine-induced signal transduction is highly
variable between primary AML samples, differing significantly
from normal hematopoietic cells. TPO, G-CSF, IL-3 and GM-
CSF were the most dominant cytokines that induced STAT5
phosphorylation, although clear specificity existed in individual
responses as well. When CD34
+/CD38
2 HSCs, CD34
+/CD38
+
MPPs and CD34
2 subfractions were taken into account
separately, we found differential responses throughout samples as
well. For example, AML 2005-289, 2003-152, 2005-258 and
2007-046 responded to cytokines especially in CD34
+ fraction
(HSCs and MPPs) but not in the CD34
2 fraction. Meanwhile, in
other AML cases it was particularly the CD34
2 population that
respondedtocytokinestimulation(e.g.AML2003-119or2003-114).
In the majority of the cases, comparable responses were detected
between HSCs and MPPs. It needs to be pointed out that even
though we followed the same definitions for HSC, CMP, GMP and
MEP in AML samples as in healthy CB and PB using CD34, CD38,
CD123 and CD45RA as antigens, these definitions of stem and
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alterations in antigen expression. These responses could not be
predicted by the presence of receptors, since in some cases no
signaling could be observed in response to a certain cytokine despite
expression of its receptor, while in other cases relatively low levels of
receptor expression correlated with a strong cytokine-induced
STAT5 response. Also, in 4 out of 5 cases, long-term expansion
on MS5 bone marrow stroma could only be established in the
presence of exogenous cytokines. In some cases, the addition of only
IL-3 (AML 2006-014) or G-CSF (AML 2003-119) was sufficient to
drive long-term expansion, but a clear (additive or in some cases
synergistic) cooperation was observed between TPO, IL-3 and
G-GSF. Clearly, the strong cytokine-induced STAT5 phosphoryla-
tion that was observed by e.g. TPO in AML 2006-014 or IL-3 in
AML 2005-289, was not sufficient to drive long-term expansion.
Apparently, besides phosphorylation of STAT5, activation of
additional signal transduction pathways was required.
In 5 out of 10 cases, we observed constitutive phosphorylation of
STAT5. Three of those cases expressed the FLT3 internal tandem
duplication (FLT3-ITD), but in two other FLT3-ITD cases no
constitutive STAT5 phosphorylation could be observed. Appar-
ently, not in all FLT3-ITD cases STAT5 is constitutively
activated, while in some FLT3-wt AMLs constitutive STAT5
phosphorylation may be observed as consequence of the autocrine
production of growth factors [20,47]. We did observe strongly
reduced cytokine responses in those AMLs characterized by
constitutive STAT5 activation. The cytokine-induced signal
transduction pathways are tightly regulated by negative feedback
regulators, including protein tyrosine phosphatases such as SHP-1,
the protein inhibitors of activated STATs (PIAS) and the
suppressor of cytokine signaling (SOCS) proteins [48]. The SOCS
family (SOCS1-7 and CIS) negatively modulates the JAK-STAT
pathway by inactivation of JAKs, blocks access of STATs to
receptor binding sites and targets proteins for ubiquitination and
degradation. Our gene expression profiling revealed that SOCS2
level was significantly higher in AMLs with constitutive STAT5
activation than those without (data not shown), suggesting a
negative feedback loop was indeed involved in case of constitu-
tively activated STAT5, rendering those cells less sensitive to
further cytokine stimulation.
In conclusion, we find that intracellular FACS analysis is an
informative tool to study cytokine-induced STAT5 phosphoryla-
tion at a single-cell level, in both normal and leukemic stem/
progenitor cells. This platform will allow a further detailed analysis
of the mechanisms by which cytokine signaling contributes to the
process of leukemic transformation in specific leukemic stem and
progenitor cell subpopulations.
Materials and Methods
Reagents and Antibodies
Paraformaldehyde (2%) (Sigma, Zwijndrecht, The Netherlands)
was dissolved in H2O and 10% PBS and filtered over 0.45 mm
filters (Millipore, Etten Leur, The Netherlands). Methanol (Merck,
Schiphol-Rijk, The Netherlands) was diluted to 90% (v/v) in PBS.
BSA was dissolved in PBS at 10% and filtered over 0.45 mm filters.
All the above reagents were aliquoted and stored at 220uC. The
following antibodies were used for FACS analyses: Alexa Fluor
647 mouse anti-Stat5 (pY694) (BD Biosciences, Breda, The
Netherlands, cat. 612599, 20 ml per sample), CD34-FITC (BD
Biosciences, Cat. 555821, 10 ml per sample), CD38-PerCP/Cy5.5
(BioLegend, Uithoorn, The Netherlands, Cat. 303522, 3 ml per
sample), CD123-PE (BioLegend, Cat. 306006, 10 ml per sample),
CD123-PE-Cy7 (BioLegend, Cat.306010, 1 ml per sample),
CD45RA-PE-Cy7 (BD Biosciences, Cat. 337186, 0.1 and 1 ml
for per fixed and unfixed sample), CD45RA-pacifc blue
(BioLegend, Cat.304118, 5 ml per sample), CD110-APC (BD
Biosciences, Cat. 551314, 7 ml per sample), CD114-PE (BD
Biosciences, Cat. 554538, 5 ml per sample), CD116-PE (BD
Biosciences, Cat. 551373, 5 ml per sample), mouse IgG1 k isotype
control labeled with APC (BD Biosciences, Cat. 555751, 7 ml per
sample), PE (BioLegend, Cat.400114, 5 ml per sample) and Alexa
647 (BD Biosciences, Cat. 557732, 20 ml per sample). Antibodies
used for Western blot were phospho-STAT5 (Tyr694) (BD
Biosciences, Cat. 611964), phospho-p44/42 MAPK (Thr202/
Tyr204) antibody (Cell Signaling, Leiden, The Netherlands, Cat.
9106), phospho-p70 S6 Kinase (Thr389) antibody (Cell Signaling,
Cat. 9205), phospho-STAT3 (Tyr705) (Cell Signaling, Cat. 9131)
and ERK1 antibody (Santa Cruz Biotechnology, CA, USA, Cat.
SC-94). Antibodies against the FcR were used to prevent aspecific
binding. (Miltenyi Biotec, Utrecht, The Netherlands)
Isolation of Normal and Leukemic CD34
+ Cells
Normal CD34
+ cells were derived from neonatal cord blood
(CB) from healthy full-term pregnancies from the Obstetrics
departments of the Martini Hospital and University Medical
Center Groningen after informed verbal consent. AML PB blasts
from untreated patients were studied after informed verbal
consent. All protocols were approved by the Medical Ethical
Committee of the UMCG, Groningen, The Netherlands. Our
Medical Ethical Committee decided that an informed verbal
consent is sufficient in order to perform studies with CB and AML
samples. After Ficoll separation of mononuclear cells (MNCs), CB
CD34
+ cells were enriched by magnetically activated cell sorting
CD34 progenitor kit (Miltenyi Biotec). Alternatively, AML MNCs
were stored in liquid nitrogen and AML CD34
+ cells were isolated
by MoFlo sorting (Dako Cytomation, Carpinteria, CA, USA).
Cytokine Stimulation and Intracellular STAT5
Phosphorylation Analysis with FACS
CB CD34
+ cells were grown in HPGM (Cambrex, Walkersville,
MD) supplemented with 100 ng/ml Stem Cell Factor (SCF;
Amgen, USA), FLT3 Ligand (FL; Amgen, USA) and Thrombo-
poietin (TPO; Kirin, Tokyo, Japan) at 5610
5 cells/ml at 37uC
and 5% CO2. After 3 days, cells were washed twice with PBS and
cytokine-depleted in HPGM at 8610
5 cells/ml overnight at 37uC.
Primary AML MNCs and PB CD34
+ cells were suspended in
HPGM at 1.5610
6 cells/ml for 2 hours at 37uC. Cells were
stimulated with cytokines for 15 minutes at 37uC after which
fixation was performed with 2% PFA at a 1:1 dilution directly into
the medium at room temperature for 10 minutes. Cells were
washed with 2% BSA/PBS twice and permeabilized with 1 ml
90% methanol on ice for 30 minutes. The permeabilized cells were
washed twice, followed by FcR blocking (1 ml per 5610
5 cells) at
4uC for 10 minutes. Samples were stained in 100 ml final reaction
volumes with the following antibodies at room temperature for
1 h: phospho-STAT5-Alexa 647; CD34-FITC; CD38-Percp/
Cy5.5; CD123-PE; CD45RA-PE-Cy7. Samples were washed
twice after incubation and analyzed on an LSR II flow cytometer
(BD). Data were analyzed using WinList 6.0 (Topsham, ME, USA)
and FlowJo (TreeStar, OR, USA) software.
The K562 cell line was cultured in RPMI 1640 medium
(Biowhittaker, Verviers, Belgium) supplemented with L-glutamate,
10% fetal calf serum (FCS; Sigma) and 1% penicillin/streptomycin
(P/S). The UT-7 cell line was cultured in IMD medium (PAA
Laboratories GmbH, Pasching, Austria) with 10% FCS and 1% P/S,
supplemented with 10 ng/ml granulocyte macrophage colony-
stimulating factor (GM-CSF; Genetics Institute, Cambrigde). The
Single-Cell STAT5 Signaling
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Cilag; Belgium) as indicated in the text. Cells were used for STAT5
phosphorylation by FACS as described above.
Long-Term Cultures on MS5 Stromal Cells
4610
4 AML CD34
+ cells were plated in 12-well plates precoated
with MS5 stromal cells as described previously [43,44]. Briefly, cells
were expanded in LTC medium including aMEM (Fisher Scientific
Europe, Emergo, The Netherlands) supplemented with heat-
inactivated 12.5% FCS, heat-inactivated 12.5% horse serum
(Sigma), 1% P/S, 2 mM glutamine, 57.2 mM b-mercaptoethanol
(Sigma) and 1 mM hydrocortisone (Sigma). The culture was
supplemented with either no cytokines or 20 ng/ml IL-3, granulo-
cyte colony-stimulating factor (G-CSF; Rhone-Poulenc Rorer,
Amstelveen, The Netherlands), TPO or in combination as described
in the text. Cultures were kept at 37uC and 5% CO2 and demi-
depopulated weekly for analysis.
Cell Lysis and Western Blotting
Whole cell lysates were prepared of 3610
5 cells by resuspending
and boiling in sample buffer (containing 2% SDS, 10% glycerol,
2% b-mercaptoethanol, 60 mM Tris-HCL pH 6.8 and bromo-
phenol blue) for 5 minutes. Protein aliquots were separated by
10% SDS-PAGE and transferred to nitrocellulose membranes
(Millipore) using a semidry electroblotter from Biorad (Veenen-
daal, The Netherlands). The membranes were blocked in PBST
containing 5% nonfat milk prior to incubation with primary
antibodies. Detection was performed with horseradish peroxidase-
conjugated secondary antibody (Dako Cytomation, Glostrup,
Denmark) and enhanced chemiluminescence (ECL) reagent
(Roche Diagnostics, Basel, Switzerland).
Supporting Information
Figure S1 Intracellular FACS analysis to study cytokine-induced
(EPO) and oncogene-induced (BCR-ABL) STAT5 tyrosine phos-
phorylation in humanhematopoieticcells.(A–C) The UT-7 cell line
was cytokine-depleted overnight from GM-CSF and subsequently
stimulated with EPO (10 U/ml). (A) The cells were stimulated for
the indicated time points, harvested and cell extracts were Western
blotted using antibodies against phospho-STAT5 (Y694) and total
STAT5 protein. (B) The cells were stimulated for the indicated time
points, fixed with paraformaldehyde (PFA) and permeablized with
ice-cold 90% methanol, followed by staining with Alexa 647 labeled
antibodies against phospho-STAT5 (Y694). The histograms
representing activated STAT5 are shown. (C) Graphic representa-
tion of the mean fluorescence intensity (MFI) of the experiment
shown in B (solid line, with fill) and quantified Western blotting
results from A (dotted line, no fill). (D–F) The BCR-ABL positive
K562 cell line was cultured in RPMI with 10% FCS and 1% P/S at
1x10E6/ml, treated with imatinib for 1 hour at increasing
concentrations as indicated. Western blotting (D) and intracellular
FACS (E) for STAT5 phosphorylation were performed. (F)
Quantified Western blotting results from D (dotted line, no fill)
andmeanfluorescenceintensity(MFI)valuesfromE(solidline,with
fill) are shown.
Found at: doi:10.1371/journal.pone.0007989.s001 (0.49 MB TIF)
Figure S2 Titration of surface markers in both fixed and unfixed
conditions. Antibodies against surface markers of CD34-FITC,
CD34-PE, CD34-APC, CD38-Percp/Cy5.5, CD38-PE-Cy5,
CD123-PE, CD123-PE-Cy7, CD45RA-PE-Cy7, CD45-Pacific
blue and CD110-PE, CD110-APC were tested in CB CD34+
cells in both unfixed and paraformaldehyde/methanol (F/M)-
treated (fixed) cells. FcR blocking was performed 10 minutes
before staining at 4uC. The percentages of the positive cells at
different concentrations of antibodies are shown.
Found at: doi:10.1371/journal.pone.0007989.s002 (0.72 MB TIF)
Figure S3 Maintaining surface marker expression after fixation
and permeabilization. (A) Antibodies against surface markers of
CD34-FITC (10 mL), CD38-Percp/Cy5.5 (3 mL), CD123-PE
(10 mL) and CD45RA-PE-Cy7 (1 mL for unfixed cells and
0.1 mL for fixed cells) were identified in CB CD34+ cells in both
unfixed and F/M-treated cells, as tested in Supplemental Figure
S2. The percentages of the positive cells are shown after optimal
titration. (B) CB CD34+ cells were analyzed in both unfixed and
F/M-treated conditions with all above antibodies. The gating
procedure and the percentage of each cell population are shown.
Found at: doi:10.1371/journal.pone.0007989.s003 (0.14 MB TIF)
Figure S4 STAT5 phosphorylation in AML cases. (A–J) Ten
AMLs were analyzed for intracellular STAT5 phosphorylation.
The mononuclear cells (MNCs) were thawed and suspended at
1.5x10E6/ml in HPGM for 2 hours at 37uC. Cells were
stimulated with cytokines for 15 minutes, followed by intracellular
FACS. (G–J) Data from 4 AMLs is shown (raw data and data
presented as multiplied value of percentage and mean fluorescence
intensity (MFI) from the cells with activated STAT5).
Found at: doi:10.1371/journal.pone.0007989.s004 (1.58 MB TIF)
Figure S5 STAT5 phosphorylation in CD123low/neg HSCs
(CD34+CD38-) and CD123high/pos HSCs. The HSC compart-
ment was further gated by the expression level of CD123, within
which STAT5 phosphorylation was analyzed as indicated.
Found at: doi:10.1371/journal.pone.0007989.s005 (0.51 MB TIF)
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